BYM | NUV | BYM / NUV | |
Gain YTD | -0.690 | 2.068 | -33% |
Net Assets | 292M | 1.83B | 16% |
Total Expense Ratio | 1.49 | 0.47 | 317% |
Turnover | 53.00 | 21.00 | 252% |
Yield | 4.98 | 4.22 | 118% |
Fund Existence | 23 years | 38 years | - |
BYM | NUV | |
---|---|---|
RSI ODDS (%) | 3 days ago82% | 3 days ago70% |
Stochastic ODDS (%) | 3 days ago76% | 3 days ago82% |
Momentum ODDS (%) | 3 days ago68% | 3 days ago69% |
MACD ODDS (%) | 3 days ago70% | 3 days ago76% |
TrendWeek ODDS (%) | 3 days ago82% | 3 days ago70% |
TrendMonth ODDS (%) | 3 days ago81% | 3 days ago74% |
Advances ODDS (%) | 6 days ago85% | 3 days ago76% |
Declines ODDS (%) | 10 days ago76% | 5 days ago76% |
BollingerBands ODDS (%) | 3 days ago86% | 3 days ago83% |
Aroon ODDS (%) | 3 days ago75% | 3 days ago70% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
ASVIX | 10.10 | 0.06 | +0.60% |
American Century Small Cap Value Inv | |||
VITSX | 152.68 | 0.67 | +0.44% |
Vanguard Total Stock Market Idx I | |||
GCLLX | 17.21 | 0.06 | +0.35% |
Goldman Sachs Enhanced U.S. Equity C | |||
VECRX | 22.33 | 0.07 | +0.31% |
Virtus KAR Equity Income R6 | |||
FBTTX | 25.58 | N/A | N/A |
Fidelity Advisor Biotechnology M |